4 ms·
Assuming that Shire has a patent on Vyvanse, then this is more like limit production of A+B and create product C that is more expensive and has an artificial mo
by pyre 15y ago
Assuming that Shire has a patent on Vyvanse, then this is more like limit production of A+B and create product C that is more expensive and has an artificial monopoly (patent). This will then drive everyone that needs products A or B to your new product C. Profit!
- refurb 15y agoI didn't get a sense from reading the article that Shire is limiting production of their branded amphetamine salts. However, you do have a point in that having more patients on a branded therapy makes a move to Vyvanse more likely.
- pyre 15y agoI was going off of this: Luckily, Shire had magically possessed enough amphetamines from their DEA quota to produce plenty of their new ADHD medication, Vyvanse. In fact, Shire doubled its third quarter profits from 2010 to 2011, with most of that increase resulting from Vyvanse sales. During this time, coinciding nicely with the Adderall shortage, Shire hiked the price of Vyvanse.
- eli 15y agoIt makes sense to want everyone move to Vyvanse which is still protected by patent, but if you can game the system so that people are still forced to buy brand-name Adderall even though the patent is expired, that works too. (Worth noting that Shire makes money on all three -- including the generic version of Adderall. Which seems more than a little suspicious)